TY - JOUR
KW - Dapsone
KW - Dihydropteroate Synthase
KW - Escherichia coli
KW - Escherichia coli Infections
KW - Humans
KW - leprosy
KW - Mycobacterium
KW - Mycobacterium Infections
KW - Tetrahydrofolate Dehydrogenase
KW - Trimethoprim
AU - Seydel J K
AB - <p>New diaminodiphenylsulfone inhibitors of dihydropteroate synthase are described with increased inhibitory activity against mycobacteria and plasmodia, whereas their side effect of methemoglobin formation could be suppressed. The optimization of diaminobenzylpyrimidines, inhibitors of dihydrofolate reductase, led to derivatives with increased inhibitory effect against mycobacteria, especially M. leprae and plasmodia. Some of these derivatives show autosynergism. Finally the combination of brodimoprim (BDP) and dapsone (DDS) was developed for the treatment of leprosy. First clinical trials in Paraguay and Ethiopia show that combinations of BDP/DDS and BDP/DDS plus rifampicin were highly effective and may become an alternative multi-drug therapy for the treatment of leprosy. The tolerance of the regimens used was generally good.</p>
BT - Journal of chemotherapy (Florence, Italy)
C1 - http://www.ncbi.nlm.nih.gov/pubmed/8195833?dopt=Abstract
DA - 1993 Dec
IS - 6
J2 - J Chemother
LA - eng
N2 - <p>New diaminodiphenylsulfone inhibitors of dihydropteroate synthase are described with increased inhibitory activity against mycobacteria and plasmodia, whereas their side effect of methemoglobin formation could be suppressed. The optimization of diaminobenzylpyrimidines, inhibitors of dihydrofolate reductase, led to derivatives with increased inhibitory effect against mycobacteria, especially M. leprae and plasmodia. Some of these derivatives show autosynergism. Finally the combination of brodimoprim (BDP) and dapsone (DDS) was developed for the treatment of leprosy. First clinical trials in Paraguay and Ethiopia show that combinations of BDP/DDS and BDP/DDS plus rifampicin were highly effective and may become an alternative multi-drug therapy for the treatment of leprosy. The tolerance of the regimens used was generally good.</p>
PY - 1993
SP - 422
EP - 9
T2 - Journal of chemotherapy (Florence, Italy)
TI - In vitro and in vivo results of brodimoprim and analogues alone and in combination against E. coli and mycobacteria.
VL - 5
SN - 1120-009X
ER -